Zomedica

Scott A. Jordan has over 30 years of experience within the life sciences and diagnostics industries including organizational management, strategic finance, business development, and product commercialization.

Prior to joining Zomedica, Scott Jordan was the CEO and Founder of S. Jordan Associates (SJA), a boutique investment bank headquartered in Chicago, Illinois, where Scott worked with life sciences and diagnostics companies to raise non-dilutive capital and private placements, close strategic partnerships, and facilitate listings on public stock exchanges. In addition to Mr. Jordan’s role as CEO and Founder of SJA, he was also Chief Financial Officer of Inomagen Therapeutics, a private biotechnology company focused on developing a gene therapy for the treatment of atrial fibrillation, where he managed the company’s cost accounting, financial planning, treasury-related activities, controllership, fiscal management, regulatory reporting requirements, and tax planning.

In his previous roles, Mr. Jordan served as Chief Business Officer / Chief Financial Officer of two biotechnology companies located in Houston, Texas, Iterion Therapeutics and Salarius Pharmaceuticals. During his time at Salarius, the company achieved pivotal financing and scientific milestones, resulting in Salarius becoming listed on NASDAQ via a reverse merger with Flex Pharma in July of 2019. Mr. Jordan also worked at Healthios Capital Markets LLC, a boutique investment bank serving the life sciences industry. Scott started his career at Abbott Laboratories in marketing and commercialization roles.